Healthcare
Roivant Sciences Ltd.(ROIV)
Live Price
Offline$30.04
+1.04% today
1Y Change
+161.92%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- $19.92B
- Revenue Growth
- -11.2%
- EPS Growth
- -104.3%
- Dividend Yield
- 0.0%
Coverage: 237 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Roivant Sciences Ltd. (ROIV) is a Healthcare stock with a market cap of $19.92B and listed on NASDAQ. The stock last traded around $30.04 and up 161.9% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of -11.2%, EPS growth of -104.3%, a dividend yield of 0.0%. What stands out right now is revenue -11.2%, EPS -104.3%, free cash flow -10.1% with operating margin -9130.5% and ROIC -23.9%. Valuation already assumes a fairly strong business story at price/sales 1496.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ROIV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-11.2% vs +7.6% peer median
Operating Margin
Below sector median
-9130.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -11.2% and EPS is at -104.3%, with operating margin around -9130.5%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 6, 2026 | +19.9% | +7.2% | +2.4% | +14.4% |
2025 Nov 10, 2025 | +12.4% | -1.3% | -2.9% | -3.5% |
2025 Aug 11, 2025 | +27.9% | +3.6% | +5.7% | +20.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROIV
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ROIV Max Drawdown
-11.21%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ROIV and SPY.
Company Overview
Roivant Sciences Ltd.
NASDAQ Global Market
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
- Leadership
- Matthew Gline
- IPO Date
- Dec 8, 2020
- Employees
- 908
- Street Address
- 11-12 St. James's Square
- Mailing
- London, SW1Y 4LB
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 2074 003 347
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1496.5
- Price/Book
- 4.5
Growth
- Revenue
- -11.2%
- EPS
- -104.3%
- Free Cash Flow
- -10.1%
Profitability
- Gross Margin
- 91.2%
- Operating Margin
- -9130.5%
- Net Margin
- -6079.9%
- ROE
- -18.3%
- ROIC
- -23.9%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 30.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.